A Low Level, Carryover Free and Wide Range, LC-MS/MS Method for Quantitation of Semaglutide from Human Plasma

Importance of the Topic

Accurate quantification of peptide drugs such as semaglutide in human plasma is essential for pharmacokinetic, bioavailability and therapeutic monitoring studies. Semaglutide, a GLP-1 analog used in type-2 diabetes and weight-loss therapy, poses analytical challenges due to nonspecific adsorption, high matrix noise and low endogenous concentrations. A robust, sensitive LC-MS/MS method addresses these issues, enabling reliable data for clinical and research applications.

Objectives and Study Overview

The primary goal was to develop and validate a carryover-free, wide-range LC-MS/MS method for semaglutide quantitation in human plasma following ICH M10 guidelines. Key aims included achieving a low limit of quantitation (LLOQ), a broad dynamic range and demonstrating precision, accuracy and specificity suitable for pharmacokinetic studies.

Methodology and Instrumentation

The method combined protein precipitation and solid-phase extraction for sample cleanup, followed by UHPLC separation and tandem mass spectrometry detection. Instrumentation and conditions:

• LC-MS/MS system: Shimadzu LCMS-8060NX with Nexera X3 autosampler
• Column: Shim-pack Scepter Claris C8, 3 µm, 2.1 × 100 mm
• Mobile phases: 1% formic acid in water (A) and 1% formic acid in methanol:acetonitrile (1:1, B)
• Gradient elution, 0.3 mL/min flow, 65 °C column temperature, 10 min run time
• ESI interface, optimized MRM transitions (m/z 1029.2 → 1302.5, CE 39; m/z 1029.2 → 1359.1, CE 36)

Key Results and Discussion

The validated method demonstrated:

• LLOQ of 0.2 ng/mL and ULOQ of 600 ng/mL with linearity (R² = 0.991)
• Precision: system %RSD <5% (n=6) for peak area and RT variation <0.1 min
• Accuracy: 85–115% for calibration levels; QC samples within ±15% RSD
• No carryover: blank after ULOQ <20% of LLOQ response

These results confirm method suitability for sensitive, reproducible semaglutide measurement in complex plasma matrices.

Benefits and Practical Applications

The developed assay offers:

• High sensitivity for low-level detection in pharmacokinetic and bioequivalence studies
• Wide dynamic range reducing re-analysis requirements
• Carryover-free operation ensuring data integrity across batches
• Applicability in drug development, therapeutic monitoring and clinical research

Future Trends and Potential Applications

Emerging directions include:

• Extension to other therapeutic peptides and biopharmaceuticals
• Integration with automated sample preparation for high-throughput labs
• Combining with high-resolution MS for structural confirmation and metabolite profiling
• Microfluidic and nanoscale separation technologies to reduce sample volume and increase sensitivity

Conclusion

A sensitive, precise and carryover-free LC-MS/MS assay for semaglutide in human plasma was successfully developed and validated. Meeting ICH M10 criteria, this method supports reliable bioanalytical assessments for clinical and research applications.

References

• Nitin Shukla, Samruddha Chavan, Nitish Suryawanshi et al. Application Note: LCMS-8060NX Method for Quantitation of Semaglutide from Human Plasma. Shimadzu Analytical (India) Pvt. Ltd., First Edition Feb 2025.